[
  {
    "ts": null,
    "headline": "Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?",
    "summary": "HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.",
    "url": "https://finnhub.io/api/news?id=f72a01c5932e10d6531d7e064b40ace7c1c4bb92a5466c833c04ffd70eae982b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761583500,
      "headline": "Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?",
      "id": 137230953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.",
      "url": "https://finnhub.io/api/news?id=f72a01c5932e10d6531d7e064b40ace7c1c4bb92a5466c833c04ffd70eae982b"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761577500,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 137230292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks to Buy Hand Over Fist in October",
    "summary": "One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.",
    "url": "https://finnhub.io/api/news?id=f8e244215c856507ca6bea0adfcfb484fb6fd9b004a97265e91fc874fd9998a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761576300,
      "headline": "3 Healthcare Stocks to Buy Hand Over Fist in October",
      "id": 137228557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.",
      "url": "https://finnhub.io/api/news?id=f8e244215c856507ca6bea0adfcfb484fb6fd9b004a97265e91fc874fd9998a8"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=64c6130ad8af3c166324d8f7cca3653059a37e2b17bfd4af11f5ceb239d83a7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573003,
      "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock",
      "id": 137228558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=64c6130ad8af3c166324d8f7cca3653059a37e2b17bfd4af11f5ceb239d83a7f"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?",
    "summary": "J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.",
    "url": "https://finnhub.io/api/news?id=5be54768e509d0d0d1c8d7d2b87be11df2dd3ab12c9cb4c23e2c170d574a4faa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571140,
      "headline": "JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?",
      "id": 137228559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.",
      "url": "https://finnhub.io/api/news?id=5be54768e509d0d0d1c8d7d2b87be11df2dd3ab12c9cb4c23e2c170d574a4faa"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial",
    "summary": "Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga",
    "url": "https://finnhub.io/api/news?id=16056140514f981fe49532f360cd7cd5630f08e48949d924cc579988790b5a47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761568014,
      "headline": "Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial",
      "id": 137228560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga",
      "url": "https://finnhub.io/api/news?id=16056140514f981fe49532f360cd7cd5630f08e48949d924cc579988790b5a47"
    }
  },
  {
    "ts": null,
    "headline": "Johnson and Johnson to spin off orthopaedics market",
    "summary": "The company announced a formal plan to explore strategic alternatives for the segment, which has resulted in the spin-off.",
    "url": "https://finnhub.io/api/news?id=5a7054786955c74d83db9a30d0a547ea88df476ce7b233f7ab6e606b5709fd4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761567893,
      "headline": "Johnson and Johnson to spin off orthopaedics market",
      "id": 137228561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company announced a formal plan to explore strategic alternatives for the segment, which has resulted in the spin-off.",
      "url": "https://finnhub.io/api/news?id=5a7054786955c74d83db9a30d0a547ea88df476ce7b233f7ab6e606b5709fd4e"
    }
  },
  {
    "ts": null,
    "headline": "New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety.",
    "url": "https://finnhub.io/api/news?id=367b93eb8b885dd720e3090cd1fe5eac5e5097ec1c89bb59c47a721c9ec8018b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761566400,
      "headline": "New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile",
      "id": 137228562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety.",
      "url": "https://finnhub.io/api/news?id=367b93eb8b885dd720e3090cd1fe5eac5e5097ec1c89bb59c47a721c9ec8018b"
    }
  },
  {
    "ts": null,
    "headline": "TREMFYA速 (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA速 (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).",
    "url": "https://finnhub.io/api/news?id=f57e80139b8706865ecd075112292ac7e6f316d38f35ea880072d70d487253fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761564600,
      "headline": "TREMFYA速 (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years",
      "id": 137228564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA速 (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).",
      "url": "https://finnhub.io/api/news?id=f57e80139b8706865ecd075112292ac7e6f316d38f35ea880072d70d487253fc"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted a",
    "url": "https://finnhub.io/api/news?id=10285a44cac51b5e6b3e8d967777a02e32aa274cfc77232e915a7dfeff8131e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761564600,
      "headline": "Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis",
      "id": 137228563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted a",
      "url": "https://finnhub.io/api/news?id=10285a44cac51b5e6b3e8d967777a02e32aa274cfc77232e915a7dfeff8131e1"
    }
  },
  {
    "ts": null,
    "headline": "Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal",
    "summary": "Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash.",
    "url": "https://finnhub.io/api/news?id=2479fb303e2d1795b154143fc7a9d8723d6883ff077f5333763acb6d4a14d652",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761557192,
      "headline": "Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal",
      "id": 137228565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash.",
      "url": "https://finnhub.io/api/news?id=2479fb303e2d1795b154143fc7a9d8723d6883ff077f5333763acb6d4a14d652"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2025",
    "summary": "If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.",
    "url": "https://finnhub.io/api/news?id=3242a30418a90de8e987e5ec748974c8698cd8960f21d5a9033997b646c5e1ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761553800,
      "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2025",
      "id": 137228566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.",
      "url": "https://finnhub.io/api/news?id=3242a30418a90de8e987e5ec748974c8698cd8960f21d5a9033997b646c5e1ef"
    }
  }
]